CN112168812B - 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途 - Google Patents
棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途 Download PDFInfo
- Publication number
- CN112168812B CN112168812B CN201910589996.7A CN201910589996A CN112168812B CN 112168812 B CN112168812 B CN 112168812B CN 201910589996 A CN201910589996 A CN 201910589996A CN 112168812 B CN112168812 B CN 112168812B
- Authority
- CN
- China
- Prior art keywords
- palmitoleic acid
- autoimmune
- composition
- tnf
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 title claims abstract description 176
- 235000021319 Palmitoleic acid Nutrition 0.000 title claims abstract description 83
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 title claims abstract description 83
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 208000027866 inflammatory disease Diseases 0.000 title abstract description 23
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 36
- 230000001363 autoimmune Effects 0.000 claims abstract description 30
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims description 20
- 201000002491 encephalomyelitis Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 102000013691 Interleukin-17 Human genes 0.000 abstract description 33
- 108050003558 Interleukin-17 Proteins 0.000 abstract description 33
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 21
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 21
- 210000003289 regulatory T cell Anatomy 0.000 abstract description 14
- 206010061218 Inflammation Diseases 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- 230000004054 inflammatory process Effects 0.000 abstract description 13
- 230000028327 secretion Effects 0.000 abstract description 12
- 238000011161 development Methods 0.000 abstract description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 description 39
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 20
- 230000002757 inflammatory effect Effects 0.000 description 19
- 238000010306 acid treatment Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 11
- 235000021314 Palmitic acid Nutrition 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 235000013373 food additive Nutrition 0.000 description 7
- 239000002778 food additive Substances 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- -1 mucate Chemical compound 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 4
- WUBBRNOQWQTFEX-UHFFFAOYSA-M 4-aminosalicylate(1-) Chemical compound NC1=CC=C(C([O-])=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 4
- 206010006448 Bronchiolitis Diseases 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 101001115699 Homo sapiens Myelin-oligodendrocyte glycoprotein Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 229910002651 NO3 Inorganic materials 0.000 description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 229920002253 Tannate Polymers 0.000 description 4
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 150000001447 alkali salts Chemical class 0.000 description 4
- 125000005210 alkyl ammonium group Chemical group 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 4
- 229940072107 ascorbate Drugs 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229940009098 aspartate Drugs 0.000 description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 4
- 229940077388 benzenesulfonate Drugs 0.000 description 4
- 229940050390 benzoate Drugs 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 4
- 229940009662 edetate Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229940050410 gluconate Drugs 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 229940049906 glutamate Drugs 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229910017053 inorganic salt Inorganic materials 0.000 description 4
- 229940070765 laurate Drugs 0.000 description 4
- 229910003002 lithium salt Inorganic materials 0.000 description 4
- 159000000002 lithium salts Chemical class 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 159000000003 magnesium salts Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 229940049964 oleate Drugs 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 229940039748 oxalate Drugs 0.000 description 4
- 229940049953 phenylacetate Drugs 0.000 description 4
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 229940114926 stearate Drugs 0.000 description 4
- 229940086735 succinate Drugs 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 4
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 229940095064 tartrate Drugs 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 229940070710 valerate Drugs 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- JYDNQSLNPKOEII-BZSWNNBUSA-N (z)-hexadec-9-enoic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O.CCCCCC\C=C/CCCCCCCC(O)=O JYDNQSLNPKOEII-BZSWNNBUSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 208000005494 xerophthalmia Diseases 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 206010016936 Folliculitis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 206010022941 Iridocyclitis Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000009053 Neurodermatitis Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 208000033464 Reiter syndrome Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- 208000006045 Spondylarthropathies Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 208000021240 acute bronchiolitis Diseases 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 201000004612 anterior uveitis Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- 201000004982 autoimmune uveitis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 208000010726 hind limb paralysis Diseases 0.000 description 2
- 102000047972 human MOG Human genes 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 201000005671 spondyloarthropathy Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100120552 Mus musculus Foxp3 gene Proteins 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005022 impaired gait Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000021354 omega 7 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途。本发明还提供了棕榈油酸用于制备预防或治疗自身免疫性疾病的组合物的用途。本发明还提供了棕榈油酸用于制备提高Foxp3表达水平的组合物的用途。本发明还提供了棕榈油酸用于制备降低TNF‑α与IL‑17分泌的组合物的用途。棕榈油酸可以显著提高Foxp3表达水平而增加调节性T细胞的数量及功能，还可以降低TNF‑α与IL‑17的分泌，控制炎症的发生发展，对自身免疫性及炎症性疾病具有治疗或预防的效果。
Description
技术领域
本发明涉及生物医药、食品和保健品领域，具体涉及棕榈油酸和/或棕榈酸用于制备提高Foxp3表达水平、降低或抑制TNF-α和/或IL-17分泌、预防或治疗炎症性疾病、自身免疫性疾病的用途。
背景技术
免疫系统的主要作用是识别和消除外来抗原，当免疫系统错误地攻击自身正常成分，则可能导致自身免疫性疾病(autoimmune diseases)。自身免疫性疾病的是指机体对自身抗原发生免疫应答而导致自身组织、器官甚至系统受损所引起的一类疾病。据估计，全球约有7.6％～9.4％的人群患有各种类型的自身免疫性疾病。在美国，每年治疗这类疾病的费用已超过500亿美元。系统性红斑狼疮和类风湿关节炎作为自身免疫性疾病中的两种典型疾病，在我国，单两种疾病的患病率分别为0.03％～0.04％和0.35％。自身免疫性疾病很难根治，大多数患者需要长期甚至终身服药。而炎症性疾病是机体受到内外致炎因子刺激及局部损伤引起的病理性病症。炎症是多种慢性疾病的发病基础，如肠胃疾病。如果病因没有去除，长期慢性炎症对癌症的诱发、促进、恶性转化、侵袭和转移过程都起到推动作用。
免疫系统紊乱在自身免疫及炎症性疾病中起着重要作用，免疫调节逐渐成为发病的中心环节。越来越多的研究发现，在生理和感染、肿瘤、移植免疫、自身免疫性疾病及炎症性疾病等病理条件下，调节性T细胞(Regulatory T cell，Treg)通过释放细胞因子IL-10和TGF-β，降低炎症细胞因子(例如：肿瘤坏死因子α(Tumor necrosis factorα，简称：TNF-α等)的产生而发挥免疫抑制效应。Foxp3属于转录因子叉头蛋白家族，作为重要的转录因子对调节性T细胞(Treg)的形成及其免疫抑制功能起到至关重要的作用。因此调节Foxp3的表达并影响调节性T细胞(Treg)的数量及功能成为治疗炎症性或自身免疫病的关键靶点及策略。但是，目前，自身免疫及炎症性疾病治疗效果不佳，主要是引起发病的危险因素众多而且药物特异性不强，副作用大。例如，目前临床使用的非甾体抗炎药是治疗类风湿关节炎的一线药物，可缓解症状，但其胃肠副作用大且不能预防关节破坏等并发症，严重影响患者生活质量，也无法对疾病的发展起到阻滞或缓解作用；白介素-2(Interleukin-2，IL-2)可以一定程度上有助于维持调节性T细胞(Treg)和效应T细胞的免疫稳态平衡，但IL-2治疗方案在临床上需静脉滴注且需严格控制剂量，细胞毒性较大，副作用极大，威胁患者生命安全，疗效欠佳。
TNF-α和白介素17(Interleukin-17，简称：IL-17)等炎症细胞因子是参与全身炎症和自身免疫性疾病的关键细胞因子。目前的研究发现，很多自身免疫及炎症性疾病都会伴随着TNF-α和/或IL-17的异常上调或紊乱表达，拮抗TNF-α和/或IL-17可以有效调控自身免疫及炎症性疾病的转归。因此，TNF-α和/或IL-17是大量炎症性疾病及自身免疫性疾病的关键治疗靶点。目前，靶向TNF-α和/或IL-17的治疗在自身免疫及炎症性疾病取得了显著的进展。如获得FDA批准的阿达木单抗可以有效缓解类风湿患者的关节损伤。但近年部分研究指出，TNF-α靶向药物长期使用，将导致表达TNF-α的细胞凋亡，从而产生严重并发感染、结核、全血细胞减少、肺纤维化等不良反应。而且TNF-α靶向药的生产成本高，价格昂贵。因此，发现新的靶向Foxp3、TNF-α和/或IL-17等全身炎症和自身免疫性疾病的关键因子的治疗技术，研发更为安全有效、经济、毒副作用小、给药方式更方便的药物或治疗技术刻不容缓。
棕榈油酸(Palmitoleic acid)和/或其前体棕榈酸作为一种ω-7单不饱和脂肪酸，存在于植物、海洋生物或细菌等微生物及其代谢物中，在营养、医药和工业上具有重要的应用价值。据报道，棕榈油酸增加细胞膜的流动性，降低血液中低密度脂蛋白胆固醇含量，减少血管中粥样硬化、斑块形成而造成的阻塞血管，从而防止心律失常和降低高血压等。另外，棕榈油酸已被证明能提高人体对胰岛素的敏感性，对糖尿病、代谢综合征有效，且没有明显的副作用。同时，棕榈油酸作为一种可以直接从饮食摄取的天然小分子，来源广泛，相比于药物注射，棕榈油酸在临床上更容易被接受，且患者耐受性、依从性会更好。但是，目前没有棕榈油酸用于预防或治疗炎症或自身免疫性疾病的相关应用的报道。
发明内容
本发明所要解决的技术问题是针对目前免疫系统紊乱中Treg相对功能不足的难题，提供一种能够提高Foxp3表达水平、降低或抑制TNF-α和/或IL-17的分泌、预防和/或治疗自身免疫性及炎症性疾病的技术方案。
为了实现上述目的，本发明提供了棕榈油酸和/或棕榈酸用于制备预防或治疗炎症性疾病的组合物的用途。
优选地，所述组合物是药物组合物、食品、保健品、皮肤护理用品或食品添加剂中的任何一种。
本发明所公开的化合物棕榈油酸(Palmitoleic acid)cas号：373-49-9，分子式：C16H30O2，结构如式(Ⅰ)所示：
优选地，所述棕榈油酸包括棕榈油酸的前体或其衍生物，所述棕榈油酸衍生物为以下中的任意一种或多种：棕榈油酸的立体异构体、互变异构体、几何异构体、氮氧化合物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药。
所述药学上可接受的盐包括酸式或碱式无机盐或有机盐。所述酸式无机盐包括盐酸盐、硫酸盐、磷酸盐、硝酸盐、碳酸盐、硼酸盐、氨基磺酸盐或氢溴酸盐。所述碱式盐包括钠盐、钾盐、锂盐、镁盐、钙盐或铵盐。所述有机盐包括乙酸盐、丙酸盐、丁酸盐、酒石酸盐、马来酸盐、羟基马来酸盐、富马酸盐、柠檬酸盐、乳酸盐、黏液酸盐、葡萄糖酸盐、苯甲酸盐、琥珀酸盐、草酸盐、苯乙酸盐、甲基磺酸盐、对甲苯磺酸盐、苯磺酸盐、对氨基水杨酸盐、天门冬氨酸盐，谷氨酸盐、依地酸盐、硬脂酸盐、棕榈酸盐、油酸盐、月桂酸盐、鞣酸盐、抗坏血酸盐、戊酸盐或烷铵盐。
优选地，所述炎症性疾病是以下的一种或多种疾病：急性或慢性器官移植排斥、移植物抗宿主病、炎性肠病、克罗恩氏病、炎症性皮肤病、多发性硬化症、胰腺炎、急性支气管炎、慢性支气管炎、急性毛细支气管炎、哮喘、慢性毛细支气管炎、骨关节炎、痛风、脊柱关节病、赖特尔综合征、银屑病性关节病毛囊炎、新生儿早产伴随的局部或系统性炎症及由细菌、真菌、病毒、微生物、病原体、寄生虫感染和/或其引起和/或伴随的炎症。
本发明还提供了棕榈油酸和/或其前体和/或其衍生物用于制备预防或治疗自身免疫性疾病的组合物的用途。
优选地，所述组合物是药物组合物、食品、保健品、皮肤护理用品或食品添加剂中的任何一种。
优选地，所述棕榈油酸包括棕榈油酸的前体和/或其衍生物，所述棕榈油酸衍生物为以下中的任意一种或多种：棕榈油酸的立体异构体、互变异构体、几何异构体、氮氧化合物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药。
所述药学上可接受的盐包括酸式或碱式无机盐或有机盐。所述酸式无机盐包括盐酸盐、硫酸盐、磷酸盐、硝酸盐、碳酸盐、硼酸盐、氨基磺酸盐或氢溴酸盐。所述碱式盐包括钠盐、钾盐、锂盐、镁盐、钙盐或铵盐。所述有机盐包括乙酸盐、丙酸盐、丁酸盐、酒石酸盐、马来酸盐、羟基马来酸盐、富马酸盐、柠檬酸盐、乳酸盐、黏液酸盐、葡萄糖酸盐、苯甲酸盐、琥珀酸盐、草酸盐、苯乙酸盐、甲基磺酸盐、对甲苯磺酸盐、苯磺酸盐、对氨基水杨酸盐、天门冬氨酸盐，谷氨酸盐、依地酸盐、硬脂酸盐、棕榈酸盐、油酸盐、月桂酸盐、鞣酸盐、抗坏血酸盐、戊酸盐或烷铵盐。
优选地，所述自身免疫性疾病为由于调节性T细胞相对功能不足引起的的自身免疫性疾病。更优选地，所述自身免疫性疾病是以下的一种或多种疾病：红斑狼疮、甲状腺功能亢进、IgA肾炎、Ⅰ型或Ⅱ型糖尿病及其并发症、口眼干燥综合征、类风湿性关节炎、单纯性肥胖、强直性脊柱炎、支气管哮喘、神经性皮炎、溃疡性结肠炎、口腔溃疡、银屑病、白癜风、白塞氏病、自身免疫性眼虹膜睫状体炎、自身免疫性湿疹、自身免疫性葡萄膜炎、自身免疫性结膜炎、自身免疫性干眼症、自身免疫性青光眼、自身免疫性白内障、过敏性鼻炎、肠易激综合征、皮肤瘙痒。
本发明还提供了棕榈油酸用于制备提高Foxp3表达水平的组合物的用途。
优选地，所述组合物是药物组合物、食品、保健品、皮肤护理用品或食品添加剂中的任何一种。
优选地，所述棕榈油酸包括棕榈油酸的前体和/或其衍生物，所述棕榈油酸衍生物为以下中的任意一种或多种：棕榈油酸的立体异构体、互变异构体、几何异构体、氮氧化合物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药。
所述药学上可接受的盐包括酸式或碱式无机盐或有机盐。所述酸式无机盐包括盐酸盐、硫酸盐、磷酸盐、硝酸盐、碳酸盐、硼酸盐、氨基磺酸盐或氢溴酸盐。所述碱式盐包括钠盐、钾盐、锂盐、镁盐、钙盐或铵盐。所述有机盐包括乙酸盐、丙酸盐、丁酸盐、酒石酸盐、马来酸盐、羟基马来酸盐、富马酸盐、柠檬酸盐、乳酸盐、黏液酸盐、葡萄糖酸盐、苯甲酸盐、琥珀酸盐、草酸盐、苯乙酸盐、甲基磺酸盐、对甲苯磺酸盐、苯磺酸盐、对氨基水杨酸盐、天门冬氨酸盐，谷氨酸盐、依地酸盐、硬脂酸盐、棕榈酸盐、油酸盐、月桂酸盐、鞣酸盐、抗坏血酸盐、戊酸盐或烷铵盐。
本发明还提供了棕榈油酸用于制备降低TNF-α和/或IL-17分泌的组合物的用途。
优选地，所述组合物是药物组合物、食品、保健品、皮肤护理用品或食品添加剂中的任何一种。
优选地，所述棕榈油酸包括棕榈油酸的前体和/或其衍生物，所述棕榈油酸衍生物为以下中的任意一种或多种：棕榈油酸的立体异构体、互变异构体、几何异构体、氮氧化合物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药。
所述药学上可接受的盐包括酸式或碱式无机盐或有机盐。所述酸式无机盐包括盐酸盐、硫酸盐、磷酸盐、硝酸盐、碳酸盐、硼酸盐、氨基磺酸盐或氢溴酸盐。所述碱式盐包括钠盐、钾盐、锂盐、镁盐、钙盐或铵盐。所述有机盐包括乙酸盐、丙酸盐、丁酸盐、酒石酸盐、马来酸盐、羟基马来酸盐、富马酸盐、柠檬酸盐、乳酸盐、黏液酸盐、葡萄糖酸盐、苯甲酸盐、琥珀酸盐、草酸盐、苯乙酸盐、甲基磺酸盐、对甲苯磺酸盐、苯磺酸盐、对氨基水杨酸盐、天门冬氨酸盐，谷氨酸盐、依地酸盐、硬脂酸盐、棕榈酸盐、油酸盐、月桂酸盐、鞣酸盐、抗坏血酸盐、戊酸盐或烷铵盐。
所述药物组合物可以是药学上可行的任一种或多种剂型，包括但不限于为片剂、胶囊剂、口服液或冻干粉剂。
优选地，上述的药物组合物中，所述药学上可接受的载体为脱脂奶、乳糖、葡萄糖、蔗糖、山梨糖醇、甘露糖、海藻糖、淀粉、阿拉伯胶、磷酸钙、藻酸盐、明胶、硅酸钙、细结晶纤维素、聚乙烯吡咯烷酮、纤维素、水、糖浆、甲基纤维素、羟基苯甲酸甲酯、羟基苯甲酸丙酯、滑石、硬脂酸镁或矿物油中的一种或多种的混合物。
经实验研究发现，棕榈油酸在免疫系统紊乱时，可显著提高Foxp3表达而增加调节性T细胞的比例，还可以降低炎症因子TNF-α和/或IL-17等的分泌，控制炎症的发生发展，对自身免疫及炎症性疾病具有预防和/或治疗和/或辅助治疗的效果。
附图说明
图1为棕榈油酸处理后小鼠Foxp3蛋白表达水平上western blot对比图。
图2为棕榈油酸处理后小鼠流式细胞分析图，其中右象限为CD4+Foxp3+(既表达CD4又表达Foxp3)占总体CD4+T细胞的百分比。
图3为棕榈油酸处理小鼠后血清中炎症因子TNF-α的表达量统计图。
图4为棕榈油酸处理小鼠后血清中炎症因子IL-17的表达量统计图。
图5为棕榈油酸处理后人PBMC培养上清中TNF-α的表达量统计图。
图6为棕榈油酸处理后人PBMC培养上清中IL-17的表达量统计图。
图7为口服棕榈油酸治疗卡介苗急性感染所致肺部炎症肺病理对比图。
图8为口服棕榈油酸治疗实验性自身免疫性脑脊髓炎(EAE)后小鼠的EAE病变分析统计对比图。
具体实施方式
下面将结合具体实施例对本发明作进一步说明。需要指出的是，由本发明中的用于治疗和/或预防自身免疫及炎症性疾病的棕榈油酸及棕榈油酸的前体和/或其衍生物或含有本发明的棕榈油酸的药物组合物、食品、保健品及食品添加剂中在施用于受试者后，都可以应用于上文所述的适应症并展现出上文所述的功能，在本发明范围内的所有剂型均已测试，下文中，仅仅是为说明，只在实施例中描述了其中一小部分，然而不应将其理解为对本发明的限制。
本发明所指的棕榈油酸及其衍生物包括但不限于以下中的任意一种或多种：棕榈油酸、棕榈油酸的立体异构体、互变异构体、几何异构体、氮氧化合物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药。
所述疾病是自身免疫性疾病，例如但不限于系统性红斑狼疮、甲状腺功能亢进、IgA肾炎、Ⅰ型或Ⅱ型糖尿病及其并发症、口眼干燥综合征、类风湿性关节炎、单纯性肥胖、强直性脊柱炎、支气管哮喘、神经性皮炎、溃疡性结肠炎、口腔溃疡、银屑病、白癜风、白塞氏病、自身免疫性眼虹膜睫状体炎、自身免疫性湿疹、自身免疫性葡萄膜炎、自身免疫性结膜炎、自身免疫性干眼症、自身免疫性青光眼、自身免疫性白内障、过敏性鼻炎、肠易激综合征、皮肤瘙痒中的一种或多种疾病。
所述疾病是炎症性疾病，例如但不限于由急性或慢性器官移植排斥、移植物抗宿主病、炎性肠病、克罗恩氏病、炎症性皮肤病、多发性硬化症、胰腺炎、急性支气管炎、慢性支气管炎、急性毛细支气管炎、慢性毛细支气管炎、骨关节炎、痛风、脊柱关节病、赖特尔综合征、银屑病性关节病、毛囊炎、新生儿早产伴随的局部或系统性炎症及细菌、真菌、病毒、病原体、微生物、寄生虫感染和/或其引起和/或伴随的炎症组合的群中的一种或多种疾病。
所述药物组合物包括但不限于为片剂、胶囊剂或口服液。所述药学上可接受的载体包括但不限于为脱脂奶、乳糖、葡萄糖、蔗糖、山梨糖醇、甘露糖、海藻糖、淀粉、阿拉伯胶、磷酸钙、藻酸盐、明胶、硅酸钙、细结晶纤维素、聚乙烯吡咯烷酮、纤维素、水、糖浆、甲基纤维素、羟基苯甲酸甲酯、羟基苯甲酸丙酯、滑石、硬脂酸镁或矿物油中的一种或多种。
本发明的棕榈油酸还可以被制成食品、保健品及食品添加剂等。所述食品、保健品及食品添加剂均含有包含棕榈油酸，包括以下中的任意一种或多种：棕榈油酸的立体异构体、互变异构体、几何异构体、氮氧化合物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药。这些食品、保健品或皮肤护理用品(如化妆品)均可用于治疗和/或预防自身免疫及炎症性疾病。
以上内容是结合本发明创造的优选实施方式对所提供技术方案所作的进一步详细说明，不能认定本发明创造具体实施只局限于上述这些说明，对于本发明创造所属技术领域的普通技术人员来说，在不脱离本发明创造构思的前提下，还可以做出若干简单推演或替换，都应当视为属于本发明创造的保护范围。
实施例1棕榈油酸提高Foxp3及TNF-α、IL-17等炎症因子表达水平的小鼠实验
1.棕榈油酸的配制
实施案例以棕榈油酸(Palmitoleic acid)为例，但不仅限于棕榈油酸，还包括以下中的任意一种或多种棕榈油酸的前体和/或其衍生物：棕榈油酸的立体异构体、互变异构体、几何异构体、氮氧化合物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药。
步骤1：取101.6mg棕榈油酸(购自Sigma公司)溶于4mlNaOH(0.1M)，配制成100mM棕榈油酸原液；
步骤2：将100mM原液加纯净水稀释成0.36mM棕榈油酸工作液，0.22μm过滤，便于后续动物实验；
2、棕榈油酸提高Foxp3表达水平及降低TNF-α、IL-17等炎症因子分泌的小鼠实验
实验动物：14只C57BL/6小鼠3～4周，精神状态良好，购自广东省实验动物中心。小鼠然后经皮下免疫注射人髓鞘少突胶质细胞糖蛋白(MOG)35-36多肽，然后将小鼠随机分成2组，每组7只，2组分别为对照组、棕榈油酸组(0.36mM)，2组小鼠分别给纯水、棕榈油酸工作液(0.36mM)，连续饮用2周。2周后处死小鼠，分别收集脾脏细胞，使用western blot检测其Foxp3蛋白的表达量，利用核内因子染色及流式细胞术检测分析脾脏细胞中表达Foxp3的CD4+T细胞的量，同时用细胞因子微球(Cytometric Bead Array,CBA)检测技术检测小鼠血清中TNF-α、IL-17A(IL-17A是IL-17的主要形式。本发明利用分析IL-17A来分析IL-17的含量)等炎症因子的含量。
实施例2棕榈油酸控制风湿性关节炎患者的TNF-α、IL-17等炎症因子分泌的实验
1、棕榈油酸的配制
配制方法同实施例1
2、棕榈油酸控制风湿性关节炎患者的TNF-α、IL-17等炎症因子分泌的实验
分离5个未治疗的风湿性关节炎患者的外周血单个核细胞(Peripheral bloodmononuclear cell，PBMC)，将PBMC铺板于96孔板中，每孔1x106个PBMC，每个病人的PBMC分两组，分别为培养基组，棕榈油酸组(0.0036mM)，培养5天后，取培养上清100μl用细胞因子微球(Cytometric Bead Array,CBA)就流式细胞检测技术检测培养上清中TNF-α、IL-17A等炎症因子的含量。
实施例3棕榈油酸控制小鼠急性炎症的实验
1、棕榈油酸的配制
配制方法同实施例1
2、棕榈油酸控制小鼠肺部急性炎症的实验
实验动物：14只C57BL/6小鼠3～4周，精神状态良好，购自广东省实验动物中心。将小鼠随机分成2组，每组7只，2组分别为对照组、棕榈油酸组(0.36mM)。随后分别用卡介苗感染两组老鼠，感染方式为滴鼻，剂量为1x107CFU/每只。2组小鼠分别给纯水、棕榈油酸工作液(0.36mM)，连续饮用2周。2周后处死小鼠，取小鼠肺组织做病理切片，苏木素-伊红(HE)染色分析肺部的炎症浸润及病损病变。
实施例4棕榈油酸控制小鼠实验性自身免疫性脑脊髓炎(EAE)的实验
1.棕榈油酸的配制
配制方法同实施例1
2.棕榈油酸控制小鼠自身免疫性脊髓炎(EAE)的实验
实验动物为14只C57BL/6小鼠3～4周，精神状态良好，购自广东省实验动物中心。小鼠然后经皮下免疫注射人髓鞘少突胶质细胞糖蛋白(MOG)35-36多肽，然后每只小鼠继续经腹腔注射200ng的百日咳毒素两次，隔1天各注射1次，然后将小鼠随机分成2组，每组7只，2组分别为喝水对照组、棕榈油酸组(0.36mM)。三周后，观察小鼠的EAE病变情况。
小鼠EAE的病变情况采用如下的打分方法：0分：无病变；1分：尾部瘫痪；2分：步伐受损和/或翻正反应受损；3分：部分的前后肢瘫痪；4分：完全的前肢或后肢瘫痪；5分：前肢瘫痪及完全的后肢瘫痪；6分：垂死或死亡。因此，打分越高说明小鼠的EAE病变越严重。
结果分析：
为分析棕榈油酸对Foxp3表达的影响，我们首先利用western blot技术分析小鼠经棕榈油酸处理后体内Foxp3表达的影响。图1为棕榈油酸处理后小鼠脾脏细胞的Foxp3蛋白水平上western blot对比图，观察到棕榈油酸组的小鼠脾脏细胞中Foxp3蛋白的表达量高于喝水的对照组小鼠。这说明，棕榈油酸可以显著提高Foxp3表达水平。为验证westernblot的发现，我们进一步利用流式细胞技术分析经棕榈油酸处理后Foxp3+T细胞的数量及比例的变化。图2为棕榈油酸处理后小鼠的流式细胞分析图，可以观察到，棕榈油酸显著增强了CD4+T细胞中Foxp3的表达，CD4+Foxp3+T细胞占脾脏总体CD4+T细胞的比例高达12.27％，而喝水对照组只有约6.45％左右；图3、图4分别为棕榈油酸处理小鼠后血清中炎症因子TNF-α、IL-17的表达量统计图。从图3、图4可以清楚地观察到，棕榈油酸处理小鼠后小鼠体内的TNF-α、IL-17的表达量均显著下降(***表示p<0.001，具有统计学差异意义)。
我们更进一步验证了TNF-α与IL-17对自身免疫性病人的的TNF-α与IL-17的表达量的调节功能。如实施例2所述，图5为棕榈油酸处理其中一例病人PBMC后培养上清中TNF-α表达量的CBA与流式细胞分析对比图。图6为棕榈油酸处理其中一例病人PBMC后培养上清中IL-17表达量的CBA与流式细胞分析对比图。从图5、图6可以观察到棕榈油酸处理后TNF-α与IL-17的荧光团(如图中黑色矩形标识)均显著分别向左迁移，其余4例病人均获得了如涂、图6相似的的结果，棕榈油酸处理均可以有效降低病人PBMC的TNF-α与IL-17的表达量。这些结果说明，说明棕榈油酸处理可显著降低例如风湿性关节炎等自身免疫性病人的PBMC中炎症因子TNF-α与IL-17的分泌或表达。
鉴于增加FoxP3的表达而增加FoxP3+调节性T细胞的数量比例以及抑制TNF-α与IL-17的分泌是控制炎症及自身免疫病及炎症的关键免疫学机制，我们进一步分析棕榈油酸是否可以有助于抑制自身免疫性疾病及(或)炎症性疾病。
为此，建立一个细菌感染小鼠诱导的肺部炎症模型并对小鼠进行棕榈油酸处理。图7为棕榈油酸治疗卡介苗急性感染的小鼠后肺病理对比图(中间2.5X图为顶层图片中的矩形区域所示的放大图，下层10X图为中间图内矩形区域所示放大图)。从图7中，我们可以看出，喝水的对照组小鼠会出现大面积的炎症渗出、出血，肺间质内可见大量炎性细胞浸润；但相较于对照组，棕榈油酸组的小鼠，炎症减轻，出血灶减少，肺泡结构完整。对比可以说明，棕榈油酸可以高效控制炎症发生发展的过程。
更进一步，分析棕榈油酸对控制自身免疫病的作用。如图8所示，小鼠在经喝棕榈油酸后，小鼠的自身免疫性脑脊髓炎的病变病损得分显著减少(***表示p<0.001，具有统计学差异意义，EAE得分越高说明病变越严重)。这说明棕榈油酸可以提高Foxp3的表达，控制炎症因子TNF-α、IL-17等的表达从而控制EAE(自身免疫性脑脊髓炎)等自身免疫病。
以上结果表明，棕榈油酸可以显著提高Foxp3表达水平而增加调节性T细胞的数量及功能，还可以降低TNF-α的分泌，控制炎症的发生发展，对自身免疫性疾病及(或)炎症性疾病具有治疗、预防及(或)辅助治疗的效果。
Claims (3)
1.棕榈油酸用于制备预防或治疗自身免疫性疾病的组合物的用途，所述自身免疫性疾病是自身免疫性脑脊髓炎。
2.根据权利要求1所述的用途，其特征在于，所述组合物是药物组合物。
3.根据权利要求1所述的用途，其特征在于，所述棕榈油酸包括棕榈油酸的药学上可接受的盐。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910589996.7A CN112168812B (zh) | 2019-07-02 | 2019-07-02 | 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途 |
| PCT/CN2019/103631 WO2021000417A1 (zh) | 2019-07-02 | 2019-08-30 | 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910589996.7A CN112168812B (zh) | 2019-07-02 | 2019-07-02 | 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112168812A CN112168812A (zh) | 2021-01-05 |
| CN112168812B true CN112168812B (zh) | 2022-07-08 |
Family
ID=73914866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910589996.7A Active CN112168812B (zh) | 2019-07-02 | 2019-07-02 | 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112168812B (zh) |
| WO (1) | WO2021000417A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116042406A (zh) * | 2023-02-28 | 2023-05-02 | 中国科学院青海盐湖研究所 | 一株高产量积累棕榈油酸的菱形藻及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1514723A (zh) * | 2001-04-11 | 2004-07-21 | Ү���о�����չ����˾ | 用于治疗炎症的脂肪醇和脂肪酸酯 |
| CN1514736A (zh) * | 2001-04-11 | 2004-07-21 | Ү���о�����չ����˾ | 用作抗原载体的抗炎性脂肪醇和脂肪酸酯 |
| CN106163511A (zh) * | 2014-01-24 | 2016-11-23 | 国立大学法人京都大学 | 含有稀有脂肪酸的抗炎剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1069525C (zh) * | 1996-10-30 | 2001-08-15 | 海南养生堂药业有限公司 | 含龟油和鳖油的组合物及其制备方法 |
| CU22693A1 (es) * | 1999-02-22 | 2001-07-31 | Ct De Histoterapia Placentaria | Composición para el tratamiento de la psoriasis y método para su obtención |
| US20040229791A1 (en) * | 2002-12-31 | 2004-11-18 | Jung San Huang | Compositions and methods of modulating TGF-beta activity by fatty acids |
-
2019
- 2019-07-02 CN CN201910589996.7A patent/CN112168812B/zh active Active
- 2019-08-30 WO PCT/CN2019/103631 patent/WO2021000417A1/zh active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1514723A (zh) * | 2001-04-11 | 2004-07-21 | Ү���о�����չ����˾ | 用于治疗炎症的脂肪醇和脂肪酸酯 |
| CN1514736A (zh) * | 2001-04-11 | 2004-07-21 | Ү���о�����չ����˾ | 用作抗原载体的抗炎性脂肪醇和脂肪酸酯 |
| CN106163511A (zh) * | 2014-01-24 | 2016-11-23 | 国立大学法人京都大学 | 含有稀有脂肪酸的抗炎剂 |
Non-Patent Citations (2)
| Title |
|---|
| Palmitoleic acid (n-7) attenuates the immunometabolic disturbances caused by a high-fat diet independently of PPARα;Camila O Souza et al.;《MEDIATORS OF INFLAMMATION》;20141231;第2014卷;第1-12页 * |
| Topical anti-inflammatory activity of palmitoleic acid improves wound healing;Weimann, Elaine et al.;《PLOS ONE》;20181011;第13卷(第10期);第1-10页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021000417A1 (zh) | 2021-01-07 |
| CN112168812A (zh) | 2021-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rigante et al. | The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever | |
| WO2021135798A1 (zh) | 桑皮苷a及其衍生物在制备保护肠道屏障的药物中的应用 | |
| EP2589382A1 (en) | Pharmaceutical composition comprising levocarnitine and dobesilate | |
| JP2018503637A (ja) | ビフェニル誘導体及びその使用 | |
| JP2021529736A (ja) | 炎症の軽減又は治療のための組成物及び方法 | |
| JP2024015132A (ja) | Ｏ－環状フィトスフィンゴシン－１－フォスフェートを含むパーキンソン病の予防又は治療用組成物 | |
| CN112168812B (zh) | 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途 | |
| JP4556009B2 (ja) | 抗炎症剤、アレルギー性疾患予防又は改善剤及び機能性食品 | |
| EP4353245A1 (en) | Composition for preventing or treating inflammatory diseases or cancer, comprising leuconostoc bacteria-derived vesicles | |
| CN116270657A (zh) | 一种预防和/或治疗胃肠道疾病的药物组合物及其用途 | |
| LU101523B1 (en) | Application of taraxasterone in a preparation of medicament for preventing and treating senile dementia | |
| LU101639B1 (en) | Application of Ilexgenin O in preparation of medicament for preventing and treating senile dementia | |
| JP4232866B2 (ja) | 細胞障害抑制剤 | |
| TWI833874B (zh) | 神經變性疾病之預防或治療藥 | |
| US10292969B2 (en) | Composition for prevention or treatment of bronchial asthma comprising PKR inhibitor as active ingredient | |
| CN106456576A (zh) | 治疗晚期非酒精性脂肪性肝炎的方法 | |
| US20240261345A1 (en) | Composition for preventing or treating inflammatory diseases or cancer, comprising leuconostoc bacteria-derived vesicles | |
| US11896603B2 (en) | Oligosaccharide as therapeutic agent for alcohol associated liver disease | |
| KR20030019060A (ko) | 비스무트 서브갈레이트를 이용하여 산화질소 합성효소생성을 저해하는 방법 | |
| CN111317746B (zh) | 一种富勒烯结构在制备治疗阿尔茨海默病的药物中的应用 | |
| US20240058393A1 (en) | Composition comprising micrococcus luteus-derived extracellular vesicle for prevention or treatment of metabolic disease | |
| CN111728961B (zh) | 一种用于治疗老年痴呆的药物组合物及其用途 | |
| US20240252469A1 (en) | Carnosine Analogs for Use in the Treatment of Metabolic Disorders | |
| CN113209108B (zh) | 7-氨基头孢烷酸或其衍生物在制备治疗和/或预防脂质代谢异常相关性疾病药物中的应用 | |
| US11369649B1 (en) | Composition for prevention or treatment of ocular diseases comprising extracellular vesicles derived from lactobacillus paracasei |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |